Pfizer (NYSE:PFE)‘s stock had its “neutral” rating reissued by equities research analysts at UBS Group in a report issued on Monday, Borsen Zeitung reports. They currently have a $43.00 price objective on the biopharmaceutical company’s stock. UBS Group’s price target points to a potential upside of 16.37% from the company’s current price.
A number of other equities research analysts also recently issued reports on the stock. Barclays reiterated a “hold” rating and issued a $41.00 target price on shares of Pfizer in a research report on Thursday, May 9th. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Morgan Stanley downgraded shares of Pfizer from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $48.00 to $40.00 in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. set a $46.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, July 29th. Fifteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $46.24.
PFE stock opened at $36.95 on Monday. Pfizer has a 12-month low of $36.41 and a 12-month high of $46.47. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. The stock has a market cap of $211.28 billion, a P/E ratio of 12.32, a price-to-earnings-growth ratio of 3.03 and a beta of 0.63. The business has a 50 day moving average of $42.42.
In related news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the transaction, the executive vice president now directly owns 489,647 shares in the company, valued at approximately $21,588,536.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Pfizer Inc bought 50,000 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Evolution Wealth Advisors LLC acquired a new position in Pfizer in the 2nd quarter valued at $34,000. IMA Wealth Inc. grew its stake in Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 477 shares during the last quarter. Winch Advisory Services LLC grew its stake in Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 336 shares during the last quarter. Ruggie Capital Group acquired a new position in Pfizer in the 4th quarter valued at $44,000. Finally, Financial Gravity Wealth Inc. grew its stake in Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the last quarter. Institutional investors and hedge funds own 71.81% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Earnings Reports
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.